Full Breakdown
Trump Administration Reclassifies State-Licensed Medical Marijuana
4/24/2026, 1:30:30 AM
Major Policy Shift in Drug Classification
On April 23, 2026, Acting Attorney General Todd Blanche announced a significant reclassification of state-licensed medical marijuana, moving it from Schedule I to Schedule III under the Controlled Substances Act. This change, directed by President Donald Trump, acknowledges marijuana as a drug with accepted medical use and a lower potential for abuse, aligning it with substances like anabolic steroids and ketamine. While this order does not legalize marijuana for medical or recreational use federally, it marks a pivotal shift in federal drug policy, particularly for the 40 states that have established medical marijuana programs.
Implications for Research and Industry
The reclassification is expected to facilitate more rigorous research into the safety and efficacy of medical marijuana, allowing researchers to obtain state-licensed products without facing federal penalties. Blanche stated that this action would expand access to medical treatment options for patients and empower doctors with better information. Additionally, the change provides significant tax relief for licensed medical marijuana operators, enabling them to deduct business expenses on federal taxes for the first time.
Background and Context
The reclassification follows decades of federal prohibition dating back to the Marihuana Tax Act of 1937. Since then, public sentiment has shifted, with a growing number of states legalizing marijuana for medical and recreational use. Currently, 24 states and Washington, D.C., have legalized recreational marijuana, while 40 states have medical marijuana systems in place. The Trump administration's move is seen as a response to this evolving landscape and a recognition of the therapeutic potential of cannabis.
Official Statements & Responses
Blanche emphasized that the Department of Justice is fulfilling President Trump's promise to enhance medical treatment options. He noted, “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.” Michael Bronstein, president of the American Trade Association for Cannabis and Hemp, hailed the decision as “the most significant federal advancement in cannabis policy in over 50 years,” asserting that it recognizes cannabis as medicine.
Criticism & Opposition
The reclassification has drawn criticism from opponents of marijuana legalization. Kevin Sabet, chief executive of Smart Approaches to Marijuana, expressed concern that the policy could send a confusing message about marijuana's health risks, stating, “With this move, we are now confronted with the most pro-drug administration in our history.” He argued that the administration's stance appears to be influenced by industry stakeholders rather than public health experts.
What's Next
An administrative hearing is scheduled for June 29, 2026, to evaluate broader changes to marijuana's status under federal law. This hearing will consider the potential for further reclassification, which could impact the regulation of marijuana across the United States.
Verbatim Quotes
- “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.” — Todd Blanche, Acting Attorney General
- “This action recognizes what Americans have long known, cannabis is medicine,” — Michael Bronstein, President of the American Trade Association for Cannabis and Hemp
- “With this move, we are now confronted with the most pro-drug administration in our history,” — Kevin Sabet, Chief Executive of Smart Approaches to Marijuana
